Medicare Spending Far Below Expectations on New Alzheimer's Drugs

Medicare is spending significantly less than anticipated on newly approved Alzheimer's disease treatments, reflecting slower-than-expected adoption rates. The sluggish uptake is primarily driven by the complexity of administering these medications and uncertainty surrounding their clinical benefits. These new drugs require specialized infusion procedures and regular monitoring, creating barriers for both patients and healthcare providers. The lower-than-expected spending raises questions about patient access and awareness of these novel treatments, which could potentially slow cognitive decline in early-stage Alzheimer's disease.